1717-LSV
Scintomics GmbH and 1717 Life Science Ventures GmbH announced today to have signed an agreement to collaborate in the development of the theranostic pair PentixaFor / PentixaTher.
PentixaPharm GmbH, based in Würzburg, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers.
Interviews: “We are delighted that in 1717 LSV we have found a strong partner with an outstanding expertise in the clinical development of precision oncologics. Taking the various recent and successful proof-of-concept studies with PentixaFor and PentixaTher in men into account, this joint venture creates optimal conditions for the effective and swift clinical development of this unrivalled and unique pair of theranostic drugs ”, said Prof. Hans-Jürgen Wester, PhD, Founder of Scintomics and Chair for Pharmaceutical Radiochemistry at the Technical University of Munich (TUM), Germany.
“The introduction of 68 Ga-PentixaFor may be regarded as a milestone for clinical PET imaging of CXCR4 expressing malignancies”, added Dr. Hakim Bouterfa Co-founder of 1717 LSV GmbH and CEO of PentixaPharm. “Now we will focus on the next major step to provide CXCR4-directed endoradiotherapy in prospective clinical trials.”
About PentixaFor / PentixaTher
This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The Gallium-68 based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukaemia, lymphoma, and multiple myeloma – but also for other solid tumors like adrenocortical carcinoma, and small cell lung cancer. In addition, other disease conditions, such as atherosclerosis, myocardial infarction, splenosis and stroke and can be targeted with this tracer. The therapeutic counterpart PentixaTher, labeled with α- or β-emitters, offers new treatment options for individualised medicine in terms of endoradiotherapy.
About Scintomics GmbH
Scintomics, based in Fuerstenfeldbruck/Munich, is a privately held company for innovative-targeted theranostics and corresponding radiopharmaceutical technologies with a strong commitment towards personalized cancer care with an exceptional pipeline of functional diagnostics and radiotherapeutics. Scintomics considers the joint venture partnership with 1717 LSV as another important milestone towards a strong positioning as radiopharmaceutical development specialist.
About 1717 LSV GmbH
1717 LSV, based in Berlin, is a privately held company with expertise in the development of targeted precision radiopharmaceuticals for the targeted diagnosis and treatment of malignant oncological diseases. By enabling novel radiopharmaceutical therapies to traverse early stages of manufacturing and clinical development, 1717 LSV brings innovative drug candidates to patients with unmet medical needs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005776/en/
Contact:
For Scintomics Saskia Kropf General Manager tel. +49 8141 150 550 s.kropf@scintomics.com www.scintomics.com For 1717 LSV Dr. Jens Kaufmann General Manager tel. +49 30 941084-422 jens.kaufmann@1717LSV.com www.1717LSV.com For PentixaPharm Dr. Hakim Bouterfa CEO tel. +49 172 6290822 or +49 931 304998310 hakim.bouterfa@1717LSV.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PennAero and Tinicum Announce Acquisition of TriMas Aerospace4.11.2025 20:17:00 CET | Press release
Tinicum, L.P. (“Tinicum”) today announced that one of its affiliates has signed an agreement to acquire the aerospace assets of TriMas Corporation (“TriMas Aerospace”), through which TriMas Aerospace will be merged with PennAero, a Tinicum portfolio company (“the Transaction”). Funds managed by Blackstone will be a minority investor in the Transaction. This investment reinforces PennAero’s strategy of partnering with its customers to provide best-in-class engineering, manufacturing, customer service and support. TriMas Aerospace is a leading provider of highly engineered fasteners and precision-machined components for mission-critical applications across the global commercial aerospace and defense industries. Backed by a portfolio of trusted brands, including Monogram Aerospace Fasteners™, Allfast Fastening Systems®, Mac Fasteners™, TFI Aerospace, TriMas Aerospace Germany, Martinic Engineering™, RSA Engineered Products™ and Weldmac Manufacturing Company, TriMas Aerospace delivers innov
BOSTON ONCOLOGY ARABIA and LOCAL CONTENT & GOVERNMENT PROCUREMENT AUTHORITY Sign Agreement to Localize Advanced Biologic Medicines in Saudi Arabia4.11.2025 19:50:00 CET | Press release
In a major step toward advancing pharmaceutical local content and national drug security, BOSTON ONCOLOGY ARABIA and the Local Content & Government Procurement Authority (LCGPA) have signed an agreement to localize the manufacture of two biosimilar medicines within the Kingdom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104239476/en/ Representatives from the Local Content & Government Procurement Authority (LCGPA) and Boston Oncology Arabia at the Global Health Exhibition 2025 in Riyadh, following the signing of an agreement to localize the manufacturing of advanced biologic medicines. The partnership builds on Boston Oncology Arabia’s fully integrated Saudi operations and its leadership in transferring global biopharma expertise to strengthen national drug security, expand local value creation, and deliver sustainable access to high-quality biologic therapies in line with Vision 2030. The signing ceremony took place
ClickHouse Acquires LibreChat to Democratize AI-Driven Analytics Through the Open-Source Agentic Data Stack4.11.2025 18:00:00 CET | Press release
ClickHouse, Inc., the company behind the world’s fastest and most popular real-time analytics database, today announced the acquisition of LibreChat, a leading open-source AI chat platform that provides a unified interface for interacting with large language models (LLMs). The acquisition brings LibreChat founder Danny Avila and his team to ClickHouse. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104505230/en/ ClickHouse acquires LibreChat: Introducing the open-source Agentic Data Stack Together, ClickHouse and LibreChat form the foundation of the open-source Agentic Data Stack, empowering teams to deploy AI agents that analyze and act on large datasets through natural language. This shift to agentic analytics is already transforming how organizations such as Shopify, Daimler Truck, Fetch, and cBioPortal leverage their data, demonstrating the immediate value in real-world applications. At Shopify, LibreChat has become c
Mouser Electronics Explores the Future of Advanced Air Mobility and Its Impact on Design4.11.2025 17:37:00 CET | Press release
Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, released its latest installment of the Empowering Innovation Together (EIT) technology series, Urban Transport Takes Flight, examining the emerging sector of Advanced Air Mobility (AAM). This series details the technology behind electric vertical takeoff and landing (eVTOL) vehicles, the challenges of infrastructure for city deployment, and the hydrogen fuel cell solutions that power the future of urban transport. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104083206/en/ Mouser explores the technology behind urban air mobility (UAM) vehicles, the challenges of infrastructure, and the fuel solutions that are powering the future of urban transport. The path for Urban Air Mobility (UAM) to transition from futuristic concept to scalable reality is constrained by barriers in form, power, and
Sparkle Clean Tech and Aquadei Launch Global Alliance to Transform Oil & Gas Water Treatment with Next-Gen Nanobubble Technology4.11.2025 17:02:00 CET | Press release
Sparkle Clean Tech (SCT)(exclusive global licensee of Siemens Energy’s oil & gas water-treatment IP) and Aquadei, LLC have formed a strategic alliance to deploy Aquadei’s proprietary nanobubble and hydrodynamic cavitation technologies to oil & gas operations globally. This partnership is set to drive advanced water treatment methods, delivering measurable operational, economic and environmental benefits across the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104652683/en/ Nanobubble Technology in Oil & Gas: Performance Advantages Nanobubbles (gas particles smaller than 200 nanometers) feature extraordinary physical surface and interfacial properties that enhance how oil and solids interact in water. When paired with SCT’s separation technologies, these ultrafine bubbles enable more efficient separation, lower chemical consumption, and greater process stability. Unlike traditional flotation systems that rely on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom